
- /
- Supported exchanges
- / US
- / SGMO.NASDAQ
Sangamo Therapeutics Inc (SGMO NASDAQ) stock market data APIs
Sangamo Therapeutics Inc Financial Data Overview
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Sangamo Therapeutics Inc data using free add-ons & libraries
Get Sangamo Therapeutics Inc Fundamental Data
Sangamo Therapeutics Inc Fundamental data includes:
- Net Revenue: 63 756 K
- EBITDA: -76 076 800
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.13
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sangamo Therapeutics Inc News

Sangamo stock holds Buy rating at H.C. Wainwright on Fabry therapy data
Investing.com - H.C. Wainwright reiterated its Buy rating and $10.00 price target on Sangamo BioSciences (NASDAQ:SGMO) following the company’s announcement of top-line results from its Phase 1/2 STA...


Sangamo rises after trial data for Fabry disease therapy
[Book with diagnosis Fabry disease and pills. Medical concept.] designer491 Shares of Sangamo Therapeutics (NASDAQ:SGMO [https://seekingalpha.com/symbol/SGMO]) traded higher in the premarket on Tuesd...

Sangamo Therapeutics Reports Positive Data From Phase 1/2 STAAR Study In Fabry Disease
(RTTNews) - Sangamo Therapeutics, Inc. (SGMO) Tuesday reported positive topline results from the registrational Phase 1/2 STAAR study of its gene therapy candidte isaralgagene civaparvovec for the tre...

Sangamo reports positive results for Fabry disease gene therapy
RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a clinical-stage biotechnology company with a market capitalization of $103 million and trailing twelve-month revenue of $64 million, annou...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.